Brief: XBiotech Says FDA Approves Xbiotech’s IND In Rheumatology
13/12/2021 13:08
Dec 13 (Reuters) - XBiotech Inc XBIT.O :
* FDA APPROVES XBIOTECH’S IND IN RHEUMATOLOGY
* XBIOTECH INC - WILL FIRST LAUNCH NATRUNIX IN A PHASE I
STUDY TO
EVALUATE DOSING FOR SUBCUTANEOUS INJECTIONS
* XBIOTECH INC - ONCE PRELIMINARY DOSING HAS BEEN
ESTABLISHED,
COMPANY PLANS TO PROCEED WITH PHASE II STUDIES IN RA
Source text for Eikon: ID:nGNX8htygL
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke